|Bid||12.73 x 900|
|Ask||12.82 x 800|
|Day's Range||12.68 - 12.92|
|52 Week Range||9.55 - 32.20|
|Beta (3Y Monthly)||2.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.75|
Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig Wheeler, President and CEO, will present at the 2019 Bank of America Merrill Lynch Healthcare Conference. The presentation is scheduled for Thursday, May 16, 2019 at 9:20 a.m. PT (12:20 p.m. ET). A webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event. Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases and advancing its late stage biosimilar portfolio.
Momenta Pharmaceuticals Inc NASDAQ/NGS:MNTAView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for MNTA with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding MNTA are favorable, with net inflows of $3.54 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
How do we determine whether Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]
Momenta (MNTA) delivered earnings and revenue surprises of -2.22% and -57.08%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 46 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
— M281 Phase 2 trials in MG and HDFN active and enrolling patients — — Data supporting M281’s mechanism in HDFN, as first anti-FcRn antibody to inhibit maternal-fetal IgG.
Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Management will host a conference call on May 2, 2019 at 8:30 a.m. ET to discuss these results and provide an update on the company. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases.
NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
CAMBRIDGE, Mass., March 28, 2019 -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to.
Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced new preclinical data for M281, its potentially best-in-class anti-FcRn antibody, was published in the American Journal of Obstetrics & Gynecology.
In 2006 Craig Wheeler was appointed CEO of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'llRead More...
Momenta (MNTA) delivered earnings and revenue surprises of 84.78% and 102.47%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?